Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol)

Systematic Reviews

Volumn 1, Issue 1, 2012, Pages

  Phillips, Robert S ^a,e   Sutton, Alex J ^b   Riley, Richard D ^c   Chisholm, Julia C ^d   Picton, Susan V ^e   Stewart, Lesley A ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

collaborative studies; febrile neutropenia; individual participant data meta analysis; paediatric oncology; predictive modelling

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; INTERLEUKIN 6; ANTIINFECTIVE AGENT;

ARTICLE; BACTEREMIA; CANCER PROGNOSIS; CANCER RISK; CAREGIVER; CLINICAL ASSESSMENT; FEVER; FOLLOW UP; HUMAN; INFECTION; INFECTION RISK; MEASUREMENT PRECISION; NEOPLASM; NEUTROPENIA; PREDICTION; RELIABILITY; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADOLESCENT; ADULT; CHILD; INFANT; META ANALYSIS; NEWBORN; PREDICTIVE VALUE; PRESCHOOL CHILD; REVIEW;

ADOLESCENT; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; FEVER; HUMANS; INFANT; INFANT, NEWBORN; INFECTION; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 84865793102     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-1-8     Document Type: Article

References (65)

1. Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JWW. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer 2006, 42:2183-2190. 10.1016/j.ejca.2006.06.006, 16919780.
2. Freycon F, Trombert-Paviot B, Casagranda L, Bertrand Y, Plantaz D, Marec-Bérard P. Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time: a follow-up of patients included in the Childhood Cancer Registry of the Rhône-Alpes region in France (ARCERRA). Pediatr Blood Cancer 2008, 50:1213-1220. 10.1002/pbc.21506, 18300318.
3. Hargrave DR, Hann IM. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J Haematol 2001, 112:293-299. 10.1046/j.1365-2141.2001.02543.x, 11167821.
4. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997, 99:580-588. 10.1046/j.1365-2141.1997.4453255.x, 9401070.
5. Baorto EP, Aquino VM, Mullen CA, Buchanan GR, DeBaun MR. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 2001, 92:909-913. 10.1002/1097-0142(20010815)92:4<909::AID-CNCR1400>3.0.CO;2-H, 11550165.
6. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996, 77:791-798. 10.1002/(SICI)1097-0142(19960215)77:4<791::AID-CNCR27>3.0.CO;2-V, 8616774.
7. Duncan C, Chisholm JC, Freeman S, Riley U, Sharland M, Pritchard-Jones K. A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East England. Pediatr Blood Cancer 2007, 49:678-681. 10.1002/pbc.21041, 17066460.
8. Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how?. BMJ 2009, 338:b375. 10.1136/bmj.b375, 19237405.
9. Royston P, Moons KGM, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ 2009, 338:b604. 10.1136/bmj.b604, 19336487.
10. Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic research: validating a prognostic model. BMJ 2009, 338:b605. 10.1136/bmj.b605, 19477892.
11. Teuffel O, Amir E, Alibhai SMH, Beyene J, Sung L. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics 2011, 127:e279-e286. 10.1542/peds.2010-0734, 21220399.
12. Phillips B, Selwood K, Lane SM, Skinner R, Gibson F, Chisholm JC. Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. Arch Dis Child 2007, 92:495-498. 10.1136/adc.2006.102699, 2066132, 17284481.
13. Boragina M, Patel H. Management of febrile neutropenia in pediatric oncology patients: a Canadian survey. Pediatr Blood Cancer 2007, 48:521-526. 10.1002/pbc.20810, 16724314.
14. Chamberlain JD, Smibert E, Skeen J, Alvaro F. Prospective audit of treatment of paediatric febrile neutropenia in Australasia. J Paediatr Child Health 2005, 41:598-603. 10.1111/j.1440-1754.2005.00729.x, 16398846.
15. Stabell N, Nordal E, Stensvold E, Gammelsrud KW, Lund B, Taxt A, Buhring F, Greve-Isdahl M, Fornebo HP, Simonsen GS, Klingenberg C. Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis 2008, 40:301-307. 10.1080/00365540701670436, 17918015.
16. Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol 2002, 39:77-85. 10.1002/mpo.10073, 12116054.
17. Ammann RA, Simon A, de Bont ESJM. Low risk episodes of fever and neutropenia in pediatric oncology: is outpatient oral antibiotic therapy the new gold standard of care?. Pediatr Blood Cancer 2005, 45:244-247. 10.1002/pbc.20287, 15747334.
18. Chisholm JC, Dommett R. The evolution towards ambulatory and day-case management of febrile neutropenia. Br J Haematol 2006, 135:3-16. 10.1111/j.1365-2141.2006.06253.x, 16925575.
19. Phillips B, Wade R, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 2010, 46:2950-2964. 10.1016/j.ejca.2010.05.024, 2981857, 20621468.
20. Phillips B, Wade R, Westwood M, Riley R, Sutton AJ. Systematic review and meta-analysis of the value of clinical features to exclude radiographic pneumonia in febrile neutropenic episodes in children and young people. J Paediatr Child Health
21. Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996, 14:919-924.
22. Santolaya ME, Alvarez AM, Becker A, Cofré J, Enríquez N, O'Ryan M, Payá E, Pilorget J, Salgado C, Tordecilla J, Varas M, Villarroel M, Viviani T, Zubieta M. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001, 19:3415-3421.
23. Ammann RA, Bodmer N, Hirt A, Niggli FK, Nadal D, Simon A, Ozsahin H, Kontny U, Kühne T, Popovic MB, Lüthy AR, Aebi C. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol 2010, 28:2008-2014. 10.1200/JCO.2009.25.8988, 20231680.
24. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002, 25:76-97. 10.1177/0163278702025001006, 11868447.
25. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010, 340:c221. 10.1136/bmj.c221, 20139215.
26. Khan KS, Bachmann LM, ter Riet G. Systematic reviews with individual patient data meta-analysis to evaluate diagnostic tests. Eur J Obstet Gynecol Reprod Biol 2003, 108:121-125. 10.1016/S0301-2115(03)00098-8, 12781397.
27. Broeze K, Opmeer B, Bachmann L, Broekmans F, Bossuyt P, Coppus S, Johnson N, Khan K, ter Riet G, van der Veen F, van Wely M, Mol B. Individual patient data meta-analysis of diagnostic and prognostic studies in obstetrics, gynaecology and reproductive medicine. BMC Med Res Methodol 2009, 9:22. 10.1186/1471-2288-9-22, 2667527, 19327146.
28. Altman DG, Riley RD. Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2005, 2:466-472.
29. Leeflang MMG, Deeks JJ, Gatsonis C, Bossuyt PMM. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008, 149:889-897. 2956514, 19075208.
30. Trivella M, Pezzella F, Pastorino U, Harris AL, Altman DG. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 2007, 8:488-499. 10.1016/S1470-2045(07)70145-6, 17513172.
31. Royston P, Parmar MK, Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med 2004, 23:907-926. 10.1002/sim.1691, 15027080.
32. Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009, 13:1-207. iii.
33. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994, 69:979-985. 10.1038/bjc.1994.192, 1969431, 8198989.
34. Steyerberg EW, Eijkemans MJ, Harrell FE, Habbema JD. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 2000, 19:1059-1079. 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.0.CO;2-0, 10790680.
35. Heney D, Lewis IJ, Evans SW, Banks R, Bailey CC, Whicher JT. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 1992, 165:886-890. 10.1093/infdis/165.5.886, 1569338.
36. Kitanovski L, Jazbec J, Hojker S, Gubina M, Derganc M. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis 2006, 25:413-415. 10.1007/s10096-006-0143-x, 16767494.
37. Soker M, Çolpan L, Ece A, Devecioǧlu C, Haspolat K. Serum levels of IL-1β, sIL-2R, IL-6, IL-8, and TNF-α in febrile children with cancer and neutropenia. Med Oncol 2001, 18:51-57. 10.1385/MO:18:1:51, 11778970.
38. Ammann RA, Hirt A, Lüthy AR, Aebi C. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003, 41:436-443. 10.1002/mpo.10320, 14515382.
39. Ammann RA, Hirt A, Lüthy AR, Aebi C. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J 2004, 23:61-67. 10.1097/01.inf.0000106782.30100.4f, 14743049.
40. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997, 99:580-588. 10.1046/j.1365-2141.1997.4453255.x, 9401070.
41. Rondinelli PIP, Ribeiro K, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 2006, 28:665-670. 10.1097/01.mph.0000212996.94929.0b, 17023827.
42. Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2002, 24:38-42. 10.1097/00043426-200201000-00011, 11902738.
43. Spasova MI, Terzieva DD, Tzvetkova TZ, Stoyanova AA, Mumdzhiev IN, Yanev IB, Genev ED. Interleukin-6, interleukin-8, interleukin-10, and C-reactive protein in febrile neutropenia in children with malignant diseases. Folia Medica (Plovdiv) 2005, 47:46-52.
44. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000, 18:1012-1019.
45. West DC, Marcin JP, Mawis R, He J, Nagle A, Dimand R. Children with cancer, fever, and treatment-induced neutropenia: risk factors associated with illness requiring the administration of critical care therapies. Pediatr Emerg Care 2004, 20:79-84. 10.1097/01.pec.0000113875.10140.40, 14758303.
46. Oude Nijhuis C, Kamps WA, Daenen SMG, Gietema JA, van der Graaf WTA, Groen HJM, Vellenga E, Ten Vergert EM, Vermeulen KM, de Vries-Hospers HG, de Bont ESJM. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol 2005, 23:7437-7444. 10.1200/JCO.2004.00.5264, 16234511.
47. Royston P, Sauerbrei W. Multivariable Model-Building: A Pragmatic Approach to Regression Anaylsis Based on Fractional Polynomials for Modelling Continuous Variables 2008, Chichester, UK: John Wiley & Sons.
48. Diepold M, Noellke P, Duffner U, Kontny U, Berner R. Performance of interleukin-6 and interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis 2008, 8:28. 10.1186/1471-2334-8-28, 2292194, 18321393.
49. Riikonen P, Saarinen UM, Teppo AM, Metsärinne K, Fyhrquist F, Jalanko H. Cytokine and acute-phase reactant levels in serum of children with cancer admitted for fever and neutropenia. J Infect Dis 1992, 166:432-436. 10.1093/infdis/166.2.432, 1378873.
50. Marshall A, Altman D, Royston P, Holder R. Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. BMC Med Res Methodol 2010, 10:7. 10.1186/1471-2288-10-7, 2824146, 20085642.
51. Marshall A, Altman D, Holder R, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009, 9:57. 10.1186/1471-2288-9-57, 2727536, 19638200.
52. Partridge N, Scadding J. The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials. Lancet 2004, 364:1923-1924. 10.1016/S0140-6736(04)17494-1, 15566996.
53. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet 2000, 355:2037-2040. 10.1016/S0140-6736(00)02351-5, 10885355.
54. Fern L, Davies S, Eden T, Feltbower R, Grant R, Hawkins M, Lewis I, Loucaides E, Rowntree C, Stenning S, Whelan J. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. Br J Cancer 2008, 99:1967-1974. 10.1038/sj.bjc.6604751, 2607227, 19034273.
55. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000, 18:3038-3051.
56. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn L, Grunberg SM, Koeller J, Oliver I, Borjeson S, Ballatori E. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005, 13:85-96. 10.1007/s00520-004-0699-x, 15565277.
57. Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ 2010, 340:c181. 10.1136/bmj.c181, 2813427, 20110312.
58. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004, 10:4-12. 10.1158/1078-0432.CCR-1051-2, 14734444.
59. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998, 52:289-303. 10.1023/A:1006193704132, 10066088.
60. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006, 144:427-437.
61. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86:829-835. 10.1093/jnci/86.11.829, 8182763.
62. Santolaya ME, Alvarez AM, Avilés CL, Becker A, Cofré J, Enríquez N, O'Ryan M, Payá E, Salgado C, Silva P, Tordecilla J, Varas M, Villarroel M, Viviani T, Zubieta M. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis 2002, 35:678-683. 10.1086/342064, 12203164.
63. Altman DG, Royston P. What do we mean by validating a prognostic model?. Stat Med 2000, 19:453-473. 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5, 10694730.
64. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4, 8668867.
65. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JPT. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343:d4002. 10.1136/bmj.d4002, 21784880.